• AIGEN Sciences

  Participated · Equity · Oct 2024

  AIGEN Sciences is an AI-driven drug discovery platform that develops small-molecule synthetic drugs targeting intractable diseases with high unmet medical needs. Founded in April 2021 and based in Seoul, the company provides drug research and development services using a proprietary AI platform. Its pipeline includes multiple lead substance optimizations and preclinical candidates. AIGEN aims to advance state-of-the-art AI drug discovery technologies and to transform high-cost, low-efficiency drug discovery into faster, more efficient processes. The company will use the funding to enhance its drug development capabilities and accelerate growth.

• NeoCannBio

  Participated · Series B · Sep 2023

  Neocannbio is a South Korean medical cannabis company backed by the Korea Institute of Science and Technology (KIST). It supplies food and cosmetics derived from cannabis cannabinoids and is actively pursuing cannabis-derived drug development with universities and CROs in Israel. The company completed a KRW 10 billion Series B that values it at around KRW 55 billion, bringing cumulative funding to KRW 15 billion in its second year. Neocannbio raised KRW 4.5 billion in a Series A last July at an approximate KRW 30 billion valuation. It plans to use the Series B proceeds to expand global sales of cannabinoid-based foods and cosmetics through a joint venture being established in Thailand and to accelerate its drug development programs. Management highlighted recent research showing efficacy for Alzheimer’s, a reported synergistic effect with liver cancer with an overseas patent filed, and joint research with HLB BioScience as it aims to become a leading cannabis company in Asia.

• Lifesprout

  Led · Seed · Jun 2018

  LifeSprout is a Baltimore-based regenerative medicine company that licensed technology from Johns Hopkins University. It has developed a proprietary Regenerative Matrix platform comprising biomimetic, biocompatible materials engineered to look and feel like natural tissue. The first product, Lumina™, is a next-generation aesthetic filler that combines the proven safety of hyaluronic acid with biostimulatory effects. The company is also developing additional cell therapy products intended to offer regenerative solutions, including treatments for patients with orphan diseases. LifeSprout closed a $28.5M Series A financing and intends to use the proceeds for clinical development of novel therapeutic products from its Regenerative Matrix platform. The company is led by co-founder Sashank Reddy, MD, PhD, with Adam Gridley serving as Executive Chairman. LifeSprout is developing a synthetic material designed to provide space for the body to regenerate its own soft tissue over time. The company aims to bring its soft tissue replacement technology to market for applications such as reconstruction after trauma or disease. Leadership includes CEO Sashank Reddy and founders Russell Martin, Hai‑Quan Mao, Justin Sacks and Sashank Reddy. The startup recently closed a financing round to support development and commercialization efforts. The article does not disclose operating metrics such as revenue or user counts.

No current team members are available.